Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Acorda Therapeutics, Inc. ACOR
$0.72
-$0.1 (-14.14%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
19713537.00000000
-
week52high
1.24
-
week52low
0.26
-
Revenue
118566000
-
P/E TTM
0
-
Beta
1.40138400
-
EPS
-3.40000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 10:59
Описание компании
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Neutral | 17 июн 2021 г. |
| H.C. Wainwright | Neutral | 06 мая 2020 г. | |
| JP Morgan | Underweight | Neutral | 24 окт 2019 г. |
| H.C. Wainwright | Neutral | Buy | 14 авг 2019 г. |
| Wedbush | Neutral | Neutral | 02 авг 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Varian John | A | 4712 | 4712 | 01 янв 2023 г. |
| Clem Kerry M | D | 10083 | 1511 | 03 сент 2022 г. |
| Sabella Lauren M | D | 10710 | 1511 | 03 сент 2022 г. |
| Randall Lorin | A | 10000 | 10000 | 10 июн 2022 г. |
| Kelley John P | A | 10000 | 10000 | 10 июн 2022 г. |
| PANEM SANDRA PHD | A | 10000 | 10000 | 10 июн 2022 г. |
| Jensen Peder | A | 10000 | 10000 | 10 июн 2022 г. |
| COHEN RON | D | 129601 | 2289 | 17 мар 2022 г. |
| Varian John | A | 20000 | 20000 | 01 янв 2022 г. |
| COHEN RON | A | 100000 | 100000 | 12 ноя 2021 г. |
Новостная лента
3 Penny Stocks to Avoid as Interest Rates Rise in 2023
InvestorPlace
11 мая 2023 г. в 14:26
Prudent investors are now forced to reassess their portfolios and risk profiles. Indeed, for those invested in penny stocks, the promise of substantial returns is great.
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
Business Wire
06 мар 2023 г. в 15:43
PEARL RIVER, N.Y.
Acorda Therapeutics, Inc. (ACOR) Q3 2022 Earnings Call Transcript
Seeking Alpha
01 ноя 2022 г. в 19:49
Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q3 2022 Results Conference Call November 1, 2022 4:30 PM ET Company Participants Tierney Saccavino - Investor Relations Ron Cohen - President and Chief Executive Officer Michael Gesser - Chief Financial Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright Operator Welcome to Acorda Therapeutics' Third Quarter 2022 Financial and Business Update.
Acorda Therapeutics supplies long-term guidance and business plan in preparation for shareholders meeting
Proactive Investors
31 окт 2022 г. в 15:29
Acorda Therapeutics Inc (NASDAQ:ACOR) has provided long-term financial guidance and an updated business plan in preparation for the special meeting of its stockholders this week, and updated its net revenue forecast from US$116 million to $121 million in 2023, and as much as $199 million by 2027. The Pearl River, New York-based company said it expects to increase the market for two of its pharmaceuticals – Inbrija for patients with Parkinson's disease, and Ampyra, used to treat adults with multiple sclerosis.
Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022
Business Wire
25 окт 2022 г. в 16:01
PEARL RIVER, N.Y.